Bicycle hydroxamic acid derivativesA compound of formula (I), wherein Z and Q are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use.The compound of formula i: wherein z is＞ch 2or＞nr 1r 1be hydrogen, (c 1-c 6) alkyl, (c 6-c 10) aryl (c 1-c 6) alkyl, (c 2-c 9) heteroaryl (c 1-c 6) group of alkyl or following formula: n is the integer of 1-6;r 2be hydrogen or (c 1-c 6) alkyl; q is (c 1-c 6) alkyl, (c 6-c 10) aryl, (c 2-c 9) heteroaryl, (c 6-c 10) aryloxy (c 1-c 6) alkyl, (c 6-c 10) aryloxy (c 6-c 10) aryl, (c 6-c 10) aryloxy (c 2-c 9) heteroaryl, (c 6-c 10) aryl (c 1-c 6) alkyl, (c 6-c 10) aryl (c 6-c 10) aryl, (c 6-c 10) aryl (c 2-c 9) heteroaryl, (c 6-c 10) aryl (c 6-c 10) aryl (c 1-c 6) alkyl, (c 6-c 10) aryl (c 6-c 10) aryl (c 6-c 10) aryl, (c 6-c 10) aryl (c 6-c 10) aryl (c 2-c 9) heteroaryl, (c 2-c 9) heteroaryl (c 1-c 6) alkyl, (c 2-c 9) heteroaryl (c 6-c 10) aryl, (c 2-c 9) heteroaryl (c 2-c 9) heteroaryl, (c 6-c 10) aryl (c 1-c 6) alkoxyl group (c 1-c 6) alkyl, (c 6-c 10) aryl (c 1-c 6) alkoxyl group (c 6-c 10) aryl, (c 6-c 10) aryl (c 1-c 6) alkoxyl group (c 2-c 9) heteroaryl, (c 2-c 9) heteroaryl oxygen base (c 1-c 6) alkyl, (c 2-c 9) heteroaryl oxygen base (c 6-c 10) aryl, (c 2-c 9) heteroaryl oxygen base (c 2-c 9) heteroaryl, (c 2-c 9) heteroaryl (c 1-c 6) alkoxyl group (c 1-c 6) alkyl, (c 2-c 9) heteroaryl (c 1-c 6) alkoxyl group (c 6-c 10) aryl, (c 2-c 9) heteroaryl (c 1-c 6) alkoxyl group (c 2-c 9) heteroaryl, (c 6-c 10) aryloxy (c 1-c 6) alkyl (c 6-c 10) aryl, (c 6-c 10) aryloxy (c 1-c 6) alkyl (c 2-c 9) heteroaryl, (c 2-c 9) heteroaryl oxygen base (c 1-c 6) alkyl (c 6-c 10) aryl or (c 2-c 9) heteroaryl oxygen base (c 1-c 6) alkyl (c 2-c 9) heteroaryl; wherein, described (c 6-c 10) aryl, (c 2-c 9) heteroaryl, (c 6-c 10) aryloxy (c 1-c 6) alkyl, (c 6-c 10) aryloxy (c 6-c 10) aryl, (c 6-c 10) aryloxy (c 2-c 9) heteroaryl, (c 6-c 10) aryl (c 1-c 6) alkyl, (c 6-c 10) aryl (c 6-c 10) aryl, (c 6-c 10) aryl (c 2-c 9) heteroaryl, (c 6-c 10) aryl (c 6-c 10) aryl (c 1-c 6) alkyl, (c 6-c 10) aryl (c 6-c 10) aryl (c 6-c 10) aryl, (c 6-c 10) aryl (c 6-c 10) aryl (c 2-c 9) heteroaryl, (c 2-c 9) heteroaryl (c 1-c 6) alkyl, (c 2-c 9) heteroaryl (c 6-c 10) aryl, (c 2-c 9) heteroaryl (c 2-c 9) heteroaryl, (c 6-c 10) aryl (c 1-c 6) alkoxyl group (c 1-c 6) alkyl, (c 6-c 10) aryl (c 1-c 6) alkoxyl group (c 6-c 10) aryl, (c 6-c 10) aryl (c 1-c 6) alkoxyl group (c 2-c 9) heteroaryl, (c 2-c 9) heteroaryl oxygen base (c 1-c 6) alkyl, (c 2-c 9) heteroaryl oxygen base (c 6-c 10) aryl, (c 2-c 9) heteroaryl oxygen base (c 2-c 9) heteroaryl, (c 2-c 9) heteroaryl (c 1-c 6) alkoxyl group (c 1-c 6) alkyl, (c 2-c 9) heteroaryl (c 1-c 6) alkoxyl group (c 6-c 10) aryl, (c 2-c 9) heteroaryl (c 1-c 6) alkoxyl group (c 2-c 9) heteroaryl, (c 6-c 10) aryloxy (c 1-c 6) alkyl (c 6-c 10) aryl, (c 6-c 10) aryloxy (c 1-c 6) alkyl (c 2-c 9) heteroaryl, (c 2-c 9) heteroaryl oxygen base (c 1-c 6) alkyl (c 6-c 10) aryl or (c 2-c 9) heteroaryl oxygen base (c 1-c 6) alkyl (c 2-c 9) each (c of heteroaryl 6-c 10) aryl or (c 2-c 9) heteroaryl moieties can randomly replace by one or more substituting groups on any ring carbon atom that can form additional key of each ring, described substituting group independently is selected from fluorine, chlorine, bromine, (c 1-c 6) alkyl, (c 1-c 6) alkoxyl group, perfluor (c 1-c 3) alkyl, perfluor (c 1-c 3) alkoxyl group and (c 6-c 10) aryloxy; or their pharmacy acceptable salt.
비사이클릭 하이드록삼산 유도체본 발명은 Z 및 Q가 본원에서 정의된 바대로인, 화학식 1의 화합물 및 이를 함유하는 약학적 조성물 및 이의 임상적 용도에 관한 것이다:화학식 1하기 화학식 1의 화합물 또는 이의 약학적으로 허용가능한 염: 화학식 1 [이미지] 상기 식에서, Z는 〉CH2 또는 〉NR1이고; R1은 수소, (C1-C6)알킬, (C6-C10)아릴(C1-C6)알킬, (C2-C9)헤테로아릴(C1-C6)알킬 또는 일반식 [이미지]의 그룹(식중, n은 1 내지 6인 정수이고; R2는 수소 또는 (C1-C6)알킬이다)이고; Q는 (C1-C6)알킬, (C6-C10)아릴, (C2-C9)헤테로아릴, (C6-C10)아릴옥시(C1-C6)알킬, (C6-C10)아릴옥시(C6-C10)아릴, (C6-C10)아릴옥시(C2-C9)헤테로아릴, (C6-C10)아릴(C1-C6)알킬, (C6-C10)아릴(C6-C10)아릴, (C6-C10)아릴(C2-C9)헤테로아릴, (C6-C10)아릴(C6-C10)아릴(C1-C6)알킬, (C6-C10)아릴(C6-C10)아릴(C6-C10)아릴, (C6-C10)아릴(C6-C10) 아릴(C2-C9)테로아릴, (C2-C9)헤테로아릴(C1-C6)알킬, (C2-C9)헤테로아릴(C6-C10)아릴, (C2-C9)헤테로아릴(C2-C9)헤테로아릴, (C6-C10)아릴(C1-C6)알콕시(C1-C6)알킬, (C6-C10)아릴(C1-C6)알콕시(C6-C10)아릴, (C6-C10)아릴(C1-C6)알콕시(C2-C9)헤테로아릴, (C2-C9)헤테로아릴옥시(C1-C6)알킬, (C2-C9)헤테로아릴옥시(C6-C10)아릴, (C2-C9)헤테로아릴옥시(C2-C9)헤테로아릴, (C2-C9)헤테로아릴(C1-C6)알콕시(C1-C6)알킬, (C2-C9)헤테로아릴 (C1-C6)알콕시(C6-C10)아릴, (C2-C9)헤테로아릴(C1-C6)알콕시(C2-C9)헤테로아릴, (C6-C10)아릴옥시(C1-C6)알킬(C6-C10)아릴, (C6-C10)아릴옥시(C1-C6)알킬(C2-C9)헤테로아릴, (C2-C9)헤테로아릴옥시(C1-C6)알킬(C6-C10)아릴 또는 (C2-C9)헤테로아릴옥시(C1-C6)알킬 (C2-C9)헤테로아릴이고, 이때 상기 (C6-C10)아릴, (C2-C9)헤테로아릴, (C6-C10)아릴옥시(C1-C6)알킬, (C6-C10)아릴옥시(C6-C10)아릴, (C6-C10)아릴옥시(C2-C9)헤테로아릴, (C6-C10)아릴(C1-C6)알킬, (C6-C10)아릴(C6-C10)아릴, (C6-C10)아릴(C2-C9)헤테로아릴, (C6-C10)아릴(C6-C10)아릴(C1-C6)알킬, (C6-C10)아릴(C6-C10)아릴(C6-C10)아릴, (C6-C10)아릴(C6-C10)아릴(C2-C9)헤테로아릴, (C2-C9)헤테로아릴(C1-C6)알킬, (C2-C9)헤테로아릴 (C6-C10)아릴, (C2-C9)헤테로아릴(C2-C9)헤테로아릴, (C6-C10)아릴(C1-C6)알콕시(C1-C6)알킬, (C6-C10)아릴(C1-C6)알콕시(C6-C10)아릴, (C6-C10)아릴(C1-C6)알콕시(C2-C9)헤테로아릴, (C2-C9)헤테로아릴옥시(C1-C6)알킬, (C2-C9)헤테로아릴옥시(C6-C10)아릴, (C2-C9)헤테로아릴옥시(C2-C9)헤테로아릴, (C2-C9)헤테로아릴(C1-C6)알콕시(C1-C6)알킬, (C2-C9)헤테로아릴(C1-C6)알콕시(C6-C10)아릴, (C2-C9)헤테로아릴(C1-C6)알콕시(C2-C9)헤테로아릴, (C6-C10)아릴옥시(C1-C6)알킬(C6-C10)아릴, (C6-C10)아릴옥시(C1-C6)알킬(C2-C9)헤테로아릴, (C2-C9)헤테로아릴옥시(C1-C6)알킬(C6-C10)아릴 또는 (C2-C9)헤테로아릴옥시(C1-C6)알킬(C2-C9)헤테로아릴의 (C6-C10)아릴 또는 (C2-C9)헤테로아릴 잔기 각각은 추가적인 결합을 형성할 수 있는 임의의 고리 탄소 원자상에서 고리 당 플루오로, 클로로, 브로모, (C1-C6)알킬, (C1-C6)알콕시, 퍼플루오로(C1-C3)알킬, 퍼플루오로(C1-C3)알콕시 및 (C6-C10)아릴옥시로 구성된 군에서 독립적으로 선택된 하나 이상의 치환체에 의해 치환되거나 치환되지 않는다.